Search bioRxiv⌕ Search

Biology subjects

Gatto, S. G.

Publications and source records attributed to Gatto, S. G..

2 recordsLinked to original sources

An Altered Glycome Shapes IgA B-Cell Responses and Gut Immunity During Intestinal Inflammation

A healthy gut immune system balances pathogen defense and tolerance to beneficial microbes. This equilibrium is sustained by coordinated mechanisms where B cells (BCs) play a central role, and secretory immunoglobulin A (SIgA) regulates microbiome composition. In ulcerative colitis (UC), impaired tolerogenic pathways result in exaggerated immune activation, epithelial dysfunction, and tissue damage; however, the contribution of BCs to disease pathogenesis remains unclear. Notably, sialylation is crucial to B-cell function, but its relevance in the intestinal IgA B-cell response has been scarcely explored. Here, we show that SIgA from active UC patients displays an inflammation-dependent reduction in (2,6)-sialylation. This desiaylation is recapitulated in dextran sodium sulfate-induced colitis, where IgA plasma cells (IgA+ PCs) and BCs exhibit a similar glycophenotype. Functional analyses reveal that BCs lacking (2,6)-sialylation on N-glycans exhibit defective differentiation into IgA PCs and diminished capacity to suppress intestinal inflammation in vivo, with increased neutrophil infiltration. Moreover, transcriptomic analyses of UC patient samples suggest a synergistic contribution of neuraminidase activity and reduced bioavailability of sialic acid precursors, leading to SIgA desialylation. Collectively, these findings uncover a glycosylation-dependent pathological circuit in which altered sialylation of SIgA and BCs disrupts their function, compromising mucosal homeostasis in intestinal inflammation.

immunology↗

A Developmental Lectin-Glycan Program Enables Early Breast Cancer Dissemination and Metastatic Onset

Early dissemination of breast cancer cells can precede clinically detectable tumor progression, yet the programs enabling this process, remain poorly understood. Here, we identify a developmental glycocheckpoint governed by the galectin-1 (GAL1)-glycan axis that is hijacked during early breast cancer dissemination. In the mammary gland, regulated GAL1 expression and glycan accessibility directed epithelial lineage specification and progesterone-induced branching morphogenesis. This program was aberrantly reactivated in early breast cancer lesions to promote epithelial plasticity, stem-like traits and metastatic competence. Mechanistically, GAL1 was enriched in mammary stem cell compartments and sustained progesterone receptor expression and activity. Genetic ablation or therapeutic inhibition of GAL1 across breast cancer models restrained early lesion progression, reduced circulating tumor cell frequency, and limited lung metastasis. Consistent with these findings, high GAL1 expression combined with low expression of the GAL1-restricting sialyltransferase ST6GAL1 was associated with poor clinical outcomes in patients. Thus, breast cancer co-opts a developmental GAL1-glycan program to disseminate early, revealing an unexpected link between mammary morphogenesis and metastatic progression and identifying GAL1 as a therapeutic vulnerability in early-stage disease.

cancer biology↗